BeiGene
BGNE
#881
Rank
A$33.26 B
Marketcap
$302.96
Share price
1.71%
Change (1 day)
0.85%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

Earnings for BeiGene (BGNE)

Earnings in 2024 (TTM): -A$1.34 B

According to BeiGene 's latest financial reports the company's current earnings (TTM) are -A$1.33 B. In 2023 the company made an earning of -A$1.82 B an increase over its 2022 earnings that were of -A$2.69 B.The earnings displayed on this page is the company's Pretax Income.

Earnings history for BeiGene from 2015 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) -A$1.34 B-26.42%
2023 -A$1.82 B-32.52%
2022 -A$2.69 B24.39%
2021 -A$2.16 B-13.21%
2020 -A$2.49 B72.69%
2019 -A$1.44 B36.01%
2018 -A$1.06 B616.83%
2017 -A$0.15 B-15.24%
2016 -A$0.18 B107.91%
2015 -A$83.81 M

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-A$27.24 M-97.95%๐Ÿ‡บ๐Ÿ‡ธ USA
-A$0.37 B-72.40%๐Ÿ‡บ๐Ÿ‡ธ USA